Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.
Wildschut MHE, Mena J, Dördelmann C, van Oostrum M, Hale BD, Settelmeier J, Festl Y, Lysenko V, Schürch PM, Ring A, Severin Y, Bader MS, Pedrioli PGA, Goetze S, van Drogen A, Balabanov S, Skoda RC, Lopes M, Wollscheid B, Theocharides APA, Snijder B.
Wildschut MHE, et al. Among authors: dordelmann c.
Nat Commun. 2023 Oct 12;14(1):6414. doi: 10.1038/s41467-023-42101-z.
Nat Commun. 2023.
PMID: 37828014
Free PMC article.